Financial anatomy of neuroscience research

Annals of Neurology

Volumn 60, Issue 6, 2006, Pages 652-659

  Dorsey, E Ray ^a   Vitticore, Philip ^a   De Roulet, Jason ^b   Thompson, Joel P ^a   Carrasco, Melisa ^b   Johnston, S Claiborne ^c   Holloway, Robert G ^a   Moses III, Hamilton ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Alerion Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOTECHNOLOGY; DEVICE; DRUG INDUSTRY; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; FUNDING; GOVERNMENT; HEALTH CARE ORGANIZATION; MEDICAL RESEARCH; NEUROPSYCHIATRY; NEUROSCIENCE; PRIORITY JOURNAL;

ANIMALS; BIOMEDICAL RESEARCH; BIOTECHNOLOGY; DRUG APPROVAL; DRUG INDUSTRY; EFFICIENCY, ORGANIZATIONAL; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NERVOUS SYSTEM DISEASES; NEUROSCIENCES; RESEARCH SUPPORT; UNITED STATES;

EID: 33845997749     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21047     Document Type: Article

References (31)

1. Moses H, Dorsey ER, Matheson DHM, Thier SO. Financial anatomy of biomedical research. JAMA 2005;294:1333-1342.
2. Johnston SC. Translation: Case study in failure. Ann Neurol 2006;59:447-448.
3. National Institutes of Health. The NIH Almanac-Appropriations. Available at: http://www.nih.gov/about/almanac/appropriationsi/ndex.htm. Accessed September 13, 2006.
4. National Institutes of Health. National Institutes of Health Price Indexes. Available at: http://officeofbudget.od.nih.gov/UI/GDP_FromGenBudget. htm. Accessed August 30, 2006.
5. Pharmaceutical Industry Profile 1998. Washington, DC: Pharmaceutical Research and Manufacturers of America, 1998.
6. Pharmaceutical Industry Profile 2000. Washington, DC: Pharmaceutical Research and Manufacturers of America, 2000.
7. Pharmaceutical Industry Profile 2002. Washington, DC: Pharmaceutical Research and Manufacturers of America, 2002.
8. Thomson CenterWatch. About Thomson CenterWatch. Available at: http://www.centerwatch.com/aboutcw.html. Accessed August 28, 2006.
9. Pharmaceutical Industry Profile 2006. Washington, DC: Pharmaceutical Research and Manufacturers of America, 2006.
10. U.S. Securities and Exchange Commission. Division of Corporation Finance: Standard Industrial Classification (SIC) code list. Available at: http://www.sec.gov/info/edgar/siccodes.htm. Accessed August 24, 2006.
11. Yahoo! Finance. Industry center-biotechnology. Available at: http://biz.yahoo.com/ic/515_cl_all.html. Accessed August 29, 2006.
12. U.S. Securities and Exchange Commission. SEC filings & forms (EDGAR). Available at: http://www.sec.gov/edgar.shtml. Accessed August 29, 2006.
13. Foundation Center. Top 50 U.S. foundations awarding grants for medical research, circa 2004. Available at: http://foundationcenter.org/findfunders/ statistics/pdf/04_fund_sub/2004/50_found_sub/f_sub_h_04.pdf. Accessed September 14, 2006.
14. U.S. Food and Drug Administration. U.S. Food and Drug Administration. Available at: www.fda.gov. Accessed August 23, 2006.
15. U.S. Food and Drug Administration. Center for Drug Evaluation and Research drug and biologic approval reports. Available it: http://www.fda.gov/ cder/rdmt/default.htm. Accessed August 28, 2006.
16. U.S. Food and Drug Administration. FDA drug approvals list. Available at: http://www.fda.gov/cder/da/da.htm. Accessed August 28, 2006.
17. U.S. Food and Drug Administration. Available at: http://www.fda.gov/cder/ da/ddpa.htm. Accessed August 28, 2006.
18. U.S. Food and Drug Administration. Center for Drug Evaluation and Research drug and biologic approvals for calendar year 2005. Available at: http://www.fda.gov/cder/rdmt/InternetNDA05.htm. Accessed August 28, 2006.
19. U.S. Food and Drug Administration. Fast track, accelerated approval and priority review. Available at: http://www.fda.gov/oashi/last.html. Accessed September 26, 2006.
20. U.S. Food and Drug Administration. Orphan product designation. Available at: http://www.fda.gov/orphan/designat/index.htm. Accessed September 26, 2006.
21. U.S. Food and Drug Administration. Center for Biologics Evaluation and Research Products. Available at: http://www.fda.gov/cber/products.htm. Accessed August 28, 2006.
22. U.S. Food and Drug Administration. Therapeutic biological products approval. Available at: http://www.fda.gov/cder/biologics/biologics_table.htm. Accessed August 28, 2006.
23. U.S. Food and Drug Administration. Glossary of terms. Available at: http://www.fda.gov/cder/drugsatfda/glossary.htm. Accessed August 28, 2006.
24. U.S. Food and Drug Administration. Center for Devices and Radiological Health Consumer Information. Available at: http://www.fda.gov/cdrh/consumer/mda/ index.html#databases. Accessed September 11, 2006.
25. U.S. Food and Drug Administration. Center for Devices and Radiological Health Consumer Information. Available at: http://www.sfda.gov/cdrh/consumer/ product.html#1. Accessed August 28, 2006.
26. Tufts Center for the Study of Drug Development. New approaches to assessing drug safety will help reduce development time and costs. Available at: http://csdd.tufts.edu/NewsEvents/NewsArticle.asp?newsid=64. Accessed September 25, 2006.
27. Booth B, Zemmel R. Prospects for productivity. Nat Rev Drug Discov 2004;3:451-457.
28. Wood AJJ. A proposal for radical changes in the drug-approval process. N Engl J Med 2006;355:618-623.
29. Johnston SC, Rootenberg JD, Katrak S, et al. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet 2006;367:1319-1327.
30. Johnston SC, Hauser SL. Basic and clinical research: what is the most appropriate weighting in a public investment portfolio? Ann Neurol 2006;60:9A-11A.
31. Martin JB. The integration of neurology, psychiatry, and neuroscience in the 21st century. Am J Psychol 2002;159:695-704.